Date: 2014-07-16
Type of information: Nomination
Compound:
Company: bluebird bio (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement:
Action mechanism:
Disease:
Details: * On July 16, 2014, bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced that Mark Vachon has joined the company’s board of directors.Over his career, Mr. Vachon has assumed a variety of leadership positions across the General Electric organization over 30 years and was a Company Officer since 1999 and a member of the Corporate Executive Council. Mr. Vachon was President and CEO of GE Healthcare Americas from 2009 to 2010 and prior to that he was President and CEO of Global Diagnostic Imaging, GE Healthcare between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was Executive Vice President and CFO at GE Healthcare.
Financial terms:
Latest news:
